PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY
Ding Xu,Jie Ding,Jun Qi
DOI: https://doi.org/10.1016/j.juro.2015.02.1285
2015-01-01
Abstract:You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-Surgical Therapy1 Apr 2015PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY Ding Xu, Jie Ding, and Jun Qi Ding XuDing Xu More articles by this author , Jie DingJie Ding More articles by this author , and Jun QiJun Qi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1285AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Some articles reported that PSA were reduced by approximately 50% after several months of treatment. However£a study from Korea found that PSA decreased by only about 36% after 1-year finasteride taking. The aim of our study was to evaluate the effect of finasteride on PSA in Chinese population. METHODS From Feb 2011 to Jan 2012, 83 BPH patients were enrolled in our study. All the patients were older than 50 years old and all of them received combined therapy (finasteride+doxazosin ). If PSA was greater than 4 ng/ml, a prostate biopsy is required to confirm whether it was benign or not. The patients with age less than 50, other drugs therapy, AUR history, prostate cancer, diabetes, acute prostatitis, history of baldder or prostate surgery were excluded from the study. All the patients were required for 1-year follow-up. PSA level and TPV was measured at the start, 6 months and 12 months, respectively. RESULTS 79 patients completed the follow up. The mean baseline PSA, PSA at 6 months and PSA at 12 months was 3.40ng/ml,1.89ng/ml and 1.87ng/ml, respectively. PSA level reduced by approximately 40% during finasteride therapy. We defined baseline PSA as PSA1, PSA at 6 months as PSA2, PSA at 12 months as PSA3. PSA1 was significantly correlated with PSA2/PSA1 and PSA3/PSA1. The higher the PSA1, the greater PSA2/PSA1 and PSA3/PSA1. However, prostate volume was not correlated with PSA1. We divided the patients into 3 groups according to PSA level. group1, 2, 3 represented the patients with PSA less than 2 ng/ml, between 2 and 4 ng/ml and greater than 4 ng/ml, respectively. Both the PSA2/PSA1 and the PSA3/PSA1 had significant difference among 3 groups. Furthermore, group 1 and group 2 both showed the farily large data variance. CONCLUSIONS When baseline PSA >4ng/ml, decreasing PSA level by approximately 50%. In such cases, doubled PSA could be used for screening. While when baseline PSA ¡Ü4ng/ml£Double PSA might not be an accurate predictor, because on one hand, PSA level deceased by only 30-40%; on the other hand, great variance in data might also affect the accuracy of prediction. Table 2. The effect of finasteride on PSA in different PSA level PSA2/PSA1 P value PSA3/PSA1 P value group 1(PSA1<2ng/ml) (n=28) 0.7100±18.99% <0.001 0.7633±33.38% <0.001 group 2(2≤PSA1<4ng/ml) (n=26) 0.5596±13.41% 0.5658±15.75% group 3(PSA1≥4ng/ml) (n=25) 0.5368±6.76% 0.5137±8.71% PSA1: PSA at baseline; PSA2: PSA at 6 months; PSA3: PSA at 12 months Table 1. Correlation among baseline PSA and other parameters r value P value PSA1 PSA2/PSA1 -0.541 <0.001 PSA1 PSA3/PSA1 -0.492 <0.001 PSA1 TPV1 0.158 0.164 PSA1 TPV2/TPV1 0.071 0.537 PSA1 TPV3/TPV1 0.061 0.591 PSA1: PSA at baseline; PSA2: PSA at 6 months; PSA3: PSA at 12 months © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e330 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ding Xu More articles by this author Jie Ding More articles by this author Jun Qi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...